Biotie: new treasury shares and cancellation of shares registered with the Trade Register

BIOTIE THERAPIES CORP.     STOCK EXCHANGE RELEASE    23 December 2014, at 9.00
am

Biotie: new treasury shares and cancellation of shares registered with the Trade
Register

The new shares issued in accordance with the resolution passed by the Board of
Directors of Biotie Therapies Corp. ("Company") on 16 December 2014 have been
registered with the Trade Register today on 23 December 2014. A total of
2,447,375 new shares ("Treasury Shares") were issued to the Company itself
without consideration for the purposes of being conveyed to employees entitled
to them pursuant to the terms and conditions of the Stock Option Plan 2011 and
the Equity Incentive Plan 2011 announced on 7 December 2011 ("Plans").

The Treasury Shares will be entered into the book-entry system maintained by
Euroclear Finland Ltd. The registered new shares can be traded together with the
Company's current series of shares on the stock exchange list of NASDAQ OMX
Helsinki Ltd on 29 December 2014.

Further, the Board of Directors of Biotie Therapies Corp. has pursuant to an
application by its Swiss subsidiary, Biotie Therapies AG, resolved to cancel
2,511,599 shares in the Company that are held as treasury shares by Biotie
Therapies AG, and which it no longer requires to settle exercises of options
under the Synosia option plan. The cancellation will be registered with the
Finnish trade register on or about 23 December 2014 and upon registration the
number of issued Biotie shares will reduce by 2,511,599 shares.

After the registration of the new shares and the cancellation of shares held by
Biotie Therapies AG with the Finnish Trade Register, Biotie will have
455,968,174 issued shares of which 450,696,015 will be outstanding shares.
Should all the new Treasury Shares be conveyed to employees, then this will
represent a 0.54 per cent of the current number of outstanding shares. The total
number of the Company's shares after the share issue held by the Company or its
fully owned subsidiary is 5,272,159 shares (1.16 per cent).

Turku, 23 December 2014

Biotie Therapies Corp.

Timo Veromaa, President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media






[HUG#1883158]